VALIUM (diazepam) by Viatris (2) is mechanism of action although the precise mechanism by which diazepam exerts its antiseizure effects is unknown, animal and in vitro studies suggest that diazepam acts to suppress seizures through an interaction with γ-aminobutyric acid (gaba) receptors of the a-type (gaba a ). Approved for epilepsy, alcohol withdrawal, seizures. First approved in 1963.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
Valium (diazepam) is a benzodiazepine small molecule that enhances GABA-A receptor signaling to suppress neuronal depolarization and prevent seizures. Approved in 1963, it treats epilepsy, seizures, and alcohol withdrawal by increasing chloride ion influx into neurons. It is one of the most established CNS depressants in pharmaceutical history.
Product is in mature/declining phase with minimal Part D spending; legacy brand team likely operating in cost-containment and lifecycle extension mode rather than growth investment.
Mechanism of Action Although the precise mechanism by which diazepam exerts its antiseizure effects is unknown, animal and in vitro studies suggest that diazepam acts to suppress seizures through an interaction with γ-aminobutyric acid (GABA) receptors of the A-type (GABA A ). GABA, the major…
Benzodiazepine
Worked on VALIUM at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants
Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With Epilepsy
Treatment Of Alcohol Withdrawal Syndrome: Dexmedetomidine Vs Diazepam In A Hospital O'horán
Pharmacokinetics and Safety Study of Diazepam Buccal Film (DBF) in Pediatric Subjects With Epilepsy
A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moValium is a legacy product with minimal job creation signals on pharma career platforms, reflecting its mature, off-patent status and commoditized competition. Career opportunities are limited to small, specialized teams managing brand maintenance, compliance, and legacy patient care at Viatris.